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Background: It is reported that nursing is one of the most vulnerable jobs for developing depression. While they
may not be clinically diagnosed as depressed, nurses often suffer from depression and anxiety symptoms, which
can lead to a low level of patient care. However, there is no rigorous evidence base for determining an effective
prevention strategy for these symptoms in nurses. After reviewing previous literature, we chose a strategy of
treatment with omega-3 fatty acids and a mindfulness-based stress management program for this purpose. We aim
to explore the effectiveness of these intervention options for junior nurses working in hospital wards in Japan.
Methods/Design: A factorial-design multi-center randomized trial is currently being conducted. A total of 120 nurses
without a managerial position, who work for general hospitals and gave informed consent, have been randomly allocated
to a stress management program or psychoeducation using a leaflet, and to omega-3 fatty acids or identical placebo pills.
The stress management program has been developed according to mindfulness cognitive therapy and consists of four
30-minute individual sessions conducted using a detailed manual. These sessions are conducted by nurses with a
managerial position. Participants allocated to the omega-3 fatty acid groups are provided with 1,200 mg/day of
eicosapentaenoic acid and 600 mg/day of docosahexaenoic acid for 90 days.
The primary outcome is the change in the total score of the Hospital Anxiety and Depression Scale (HADS), determined
by a blinded rater via the telephone at week 26. Secondary outcomes include the change in HADS score at 13 and 52
weeks; presence of a major depressive episode; severity of depression, anxiety, insomnia, burnout, and presenteeism;
utility scores and adverse events at 13, 26 and 52 weeks.
Discussion: An effective preventive intervention may not only lead to the maintenance of a healthy mental state in nurses,
but also to better quality of care for inpatients. This paper outlines the background and methods of a randomized trial that
evaluates the possible additive value of omega-3 fatty acids and a mindfulness-based stress management program for
reducing depression in nurses.
Trial registration: Clinicaltrials.gov: NCT02151162 (registered on 27 May 2014).
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Hospital nurses are vulnerable to psychological stress and
mental disorders [1]. In early reports, the suicide rate of fe-
male nurses was significantly higher than that of average
workers, and their life expectancy at the age of 45 years was
26.9 years, which is only one year more than that of miners
[2]. In a cross-sectional survey conducted in Cyprus, 65% of
nurses reported that their job was stressful, and the preva-
lence of fatigue was higher in females (93%) than in males
(88%) [3].
Consequently, nursing is highly associated with depres-
sion. The prevalence of depressive symptoms above a clin-
ical cut-off among hospital-employed nurses is 18% in the
United States [4]. Nurses with depression are not only
likely to suffer personally, but their illness may also have
an impact on the quality of care for patients, through an
increase in presenteeism. In terms of the monetary burden
of patient care, the costs due to increased falls and medi-
cation errors that are caused by presenteeism are esti-
mated at 1,346 USD per nurse annually [5].
A systematic review conducted on psychological distress
among hospital nurses in the United States reported that
emotional fatigue and burnout in nurses is associated with
lack of support from senior management in the form of
safety programs, and support from supervisors, respectively
[6]. Less-experienced junior nurses need support from se-
nior colleagues and require interventions to empower resili-
ence in order to alleviate their psychological distress.
When considering the possible options for intervention in
depression, pharmacological treatments can be discounted
because they are not useful as a preventive intervention due
to their adverse side effects. Instead, lifestyle interventions,
such as exercise and diet, are highly likely to be easily imple-
mented and are promising options. With regard to exercise,
according to a systematic review of randomized controlled
trials (RCTs), depressive symptoms among patients with a
chronic illness and functioning problems were reduced [7];
however, rigorous evidence has not supported exercise as a
preventive measure for depression and anxiety symptoms
among the elderly [8] or children and young people [9]. In
addition, intensive exercise may not be feasible due to the
busy schedule of nurses working in hospitals. In contrast,
the most feasible interventions may be diet. Omega-3 poly-
unsaturated fatty acids (PUFAs), in particular eicosapenta-
enoic acid (EPA) and docosahexaenoic acid (DHA), have
been most frequently evaluated for their effects on depres-
sion and anxiety disorders. Many previous systematic re-
views that have accumulated data from RCTs have been
published; however, there are some reviews that show a
positive effect of omega-3 PUFAs [10] and others that do
not [11]. In addition, these reviews did not focus on pre-
ventative interventions.
In a recently published comprehensive meta-analysis [12],
omega-3 PUFAs were effective in patients with a diagnosisof major depressive disorder, but not effective at preventing
depression in healthy subjects. In this analysis, three parallel
design RCTs for the prevention of depression in healthy
subjects were assessed, with a follow-up duration of over
three months. The studies employed a daily dose of 1.093 g
EPA and 0.226 g DHA [13], 3.0 g EPA and 0.6 g DHA [14]
or 3.0 g EPA and 0.6 g DHA [15]. However, a high daily
EPA dose of between 1,000 and 1,500 mg/d with a ratio of
2:1 DHA is argued as optimal for affective disorders [16].
Based on the current evidence for omega-3 PUFAs as a pre-
ventive tool for anxiety and depressive symptoms, we believe
that methodologically rigorous trials employing optimal
doses of EPA and DHA are still needed.
On the other hand, psychological interventions, such as
stress management, problem solving and support should
be considered as possible interventions in workplace
settings because of their feasibility and accessibility. A
Cochrane review [17] has revealed that a psychological
intervention to alleviate stress among workers in the
workplace can be efficacious according to several small
RCTs; however, this review concluded that the methodo-
logical quality of these trials was not sufficient, and further
methodologically sound trials with a larger sample size are
needed to reach firm conclusions.
Among the various types of psychotherapy, mindfulness-
based cognitive therapy and meditation have been given
particular attention by both clinicians and researchers. In a
systematic review, mindfulness meditation programs have
shown moderate evidence of improvements in depression,
with an effect size of 0.30 (95% confidence interval (CI): 0.00
to 0.59) at post-treatment), when compared with nonspecific
active controls [18]; however, the review focused on a clin-
ical sample and therefore was not able to conclude any pre-
ventive effects of the psychotherapy. To the best of our
knowledge, there has been no systematic review focusing on
the prevention of depression and anxiety symptoms in the
workplace. Although the efficacy of mindfulness-based cog-
nitive therapy in nurses has been examined in a previous
RCT [19], the trial included only a small number of partici-
pants and no firm conclusions could be drawn. For this rea-
son, a conclusive RCT is necessary to establish evidence of
an effective psychological intervention that can help to
maintain a healthy mental state in hospital nurses.
Hence, the present study aims to conduct a methodo-
logically rigorous factorial-design trial with 1:1:1:1 allo-
cation to explore the effectiveness of omega-3 PUFAs,
and a mindfulness-based stress management program
for maintaining a healthy mental state in hospital nurses.
Methods/Design
Trial design
A parallel-arms factorial-design RCT with a 52-week
follow-up period has been planned. Participants will be
randomly allocated to one of the four intervention arms:
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omega-3 PUFAs; 2) mindfulness-based stress management
program plus placebo; 3) psychoeducation leaflet plus
omega-3 PUFAs and 4) psychoeducation leaflet plus pla-
cebo. A total of 30 participants will be allocated to each
arm. These interventions will terminate within three
months from the registration of the participant. The pri-
mary outcome will be the depression and anxiety severity
at 26 weeks (rated blindly), assessed using the 14-item
Hospital Anxiety and Depression Scale (HADS). After
each assessment, an assessor will guess which group the
participant has been assigned to, making it possible to
examine if the blinding is successful.
Inclusion criteria
The inclusion criteria for participants are as follows:
1. Aged between 20 and 59 years at entry to the study
and of female gender. We will limit participants to the
female gender because a previous study investigating
the prevention of post-traumatic stress among emer-
gency workers has demonstrated that omega-3 fatty
acids are effective in females but not males [20]. This
is the first study to examine the effectiveness of
omega-3 fatty acids among nurses, therefore we have
decided to focus on females to maximize the benefit.
2. Nurses who work in inpatient wards at four general
hospitals in the Tama region of Japan, including the
National Center of Neurology and Psychiatry
Hospital, National Disaster Medical Center, Tokyo
Metropolitan Tama Medical Center and Tama-
Hokubu Medical Center.
3. Those who are mainly engaged in caring for
patients, but not in administrative responsibilities.
Thus, head nurses in wards and senior nurses who
are mainly engaged in supporting administrative
work of the head nurses are excluded. A previous
study has shown that senior nurses have less
burnout than junior nurses [21], and senior nurses
are engaged in administrative work in the hospitals
included in our study.
4. Those who have given written informed consent to
participate in the study.
Exclusion criteria
The exclusion criteria are as follows:
1. Plans to take sick leave, leave for other reasons or
retirement within 26 weeks from entry to the study;
2. Already engaging in structured psychotherapy (such
as cognitive behavioral therapy, interpersonal
therapy or brief psychodynamic therapy) at entry;
3. Seeing a physician regularly for the treatment of any
mood or anxiety disorders at entry;4. Taking antidepressants, mood stabilizers,
anticonvulsants or antipsychotics at entry;
5. Any history of taking nutrient supplements,
including omega-3 fatty acids, for four or more
weeks within 52 weeks from entry;
6. Clinical depression, based on a total score of 11 or
more on the HADS - Depression Subscale [22] and
15 or more on the Primary Health Care Question-
naire [23];
7. Consumption of fish as the main course of a meal
four or more times per a week;
8. Taking anticoagulant drugs at entry or history of
stroke or myocardial infarction or
9. Judged ineligible by a clinical research coordinator
(CRC) for any reason.
Procedures
Information about the study will be presented to the
head of the hospital, the director of the nursing service
department and head nurses in explanatory meetings at
the recruiting hospitals. Leaflets with information about
the study will be distributed to nurses in hospital wards
and interested nurses will be contacted by a CRC. Each
nurse will input her data, except the HADS criterion,
into an electronic data capturing (EDC) system via the
internet, with some assistance by the CRC, and if she
satisfies all of the inclusion criteria and none of the ex-
clusion criteria, provisional written informed consent
will be obtained. The participants will then be inter-
viewed using the HADS through their mobile phone by
a rater located in Kyoto University. If the nurse does not
satisfy the HADS exclusion criterion, formal written in-
formed consent will be obtained.
The participants will be randomly allocated to one of the
four intervention arms via the EDC using a minimization
method. Minimization is an adaptive stratified allocation
system that is used in clinical trials [24]. Minimization can
reduce the imbalance between the numbers of patients in
each treatment group over possible confounding factors.
The participant’s place of work, total score on the HADS of
11 or higher [22], and whether they have been working as a




In the present factorial-design RCT, the effects of two
forms of psychological intervention will be compared:
mindfulness-based stress management program and a psy-
choeducation leaflet.
The stress management program has been developed
combining mindfulness-based self-regulation of atten-
tion [25] and the cognitive behavioral model of depres-
sion adapted from a previously established manual [26].
Figure 1 Flowchart of the trial. EDC, electronic data capturing.
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employed mindfulness meditation with the non-judgmental
awareness of moment-to-moment experiences as the cen-
tral axis [28], we extracted the treatment components of
body scan and breathing meditation from mindfulness
meditation because these techniques are considered easy to
learn and helpful for nurses, in our experience. The stress
management program consists of four weekly 30-minute
individual sessions and is highly structured, with a detailed
manual. The contents of each session are as follows: 1) un-
derstanding the cognitive behavioral model of stress and
emotion of the participant, 2) reviewing the model and con-
ducting body scanning and breathing exercises, 3) review-
ing the results of model and body scanning and then
promoting awareness of the cognition of the participant
and 4) reviewing the model, providing suggestions about in-
creasing pleasant behaviors and planning a strategy to man-
age future stress. The feasibility of the program has been
examined by employing five nurses as participants in a pilot
run, the protocol of which was approved by the institu-
tional review boards of the National Center of Neurology
and Psychiatry on 15 November 2013 (approval number:
A2013-102). No dropouts due to the program were ob-
served. All the participants reported that the program
might be helpful for nurses to manage stress from their
work. Some rewordings have been done to the program ac-
cording to comments from the participants.
The stress management program will be conducted by se-
nior nurses in four individual sessions within the first three
months. Senior nurses will have taken a seven-hour work-
shop, including lectures and role-playing sessions. The
detailed manual and videos, including lectures, will be pro-
vided to the senior nurses. The senior nurses will be super-
vised monthly by email once the program commences. All
sessions will be audiotaped and 20% of them will berandomly selected and evaluated by two independent re-
searchers to assess the integrity of the program. They will
check for adherence to the treatment manual with a check-
list for each session.
A leaflet has been prepared for the psychoeducation
leaflet groups. This is based on a freely distributed psy-
choeducation leaflet about healthy mental state written
by the Japanese Ministry of Health, Labor and Welfare
[29]. The leaflet includes information about checking for
signs of stress, relaxation and sleep hygiene, and sugges-
tions for stress management such as exercise, laughter
and meeting intimate friends. It also includes a list of
consultants for mental health. We have adapted this
leaflet to be applicable to our study by adding advice
from senior nurses about working without stress. Partici-
pants allocated to the leaflet groups will be instructed to
read this often, especially when they feel anxious or
stressed.
Supplements interventions
Omega-3 PUFA capsules have been formulated to con-
tain 1,200 mg EPA and 600 mg DHA (Kentech Co. Ltd.,
Toyama, Japan) according to recommendations from ex-
perts [16]. The participants will take the capsules once a
day for 90 days from entry into the study. Placebo cap-
sules contain rapeseed oil (47%), soybean oil (25%), olive
oil (25%) and fish oil (3%), and have an identical appear-
ance and similar odor (Kentech Co. Ltd., Toyama,
Japan).
Adherence to the regimens will be checked among
nurses working for the National Center of Neurology
and Psychiatry Hospital and National Disaster Medical
Center from results of blood tests. At baseline and at
the three-month assessment, red blood cells (RBCs) will
be obtained from EDTA-anticoagulated blood (Terumo
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and frozen at −80°C until analysis. The fatty acid com-
position of the total phospholipid fraction of the RBCs
will be determined as described previously, with slight
modifications [30]. Briefly, the total lipid content will be
extracted from RBCs according to the method used by
Bligh and Dyer [31]. The total phospholipid fraction will
be separated by thin-layer chromatography. After trans-
methylation with HCl-methanol, the fatty acid compos-
ition will be analyzed using a gas chromatography
system (GC14A Shimadzu Corporation, Kyoto, Japan)
equipped with a capillary column DB-225 (length: 30 m;
internal diameter: 0.25 mm; film: 0.25 μm; J&W Scien-
tific, Folsom, California, United States); the entire system
was controlled using gas chromatography software
CLASS-GC10 version 1.3 (Shimadzu Corporation). In
addition, to assess adherence to the regimen, all the
remaining capsules will be collected from all the partici-
pants after the three-month assessment.
Participants who decide to leave the allocated inter-
vention due to adverse events or any other reason within
the first 13 weeks will be classified as dropouts from the
intervention, but will still be asked to complete the as-
sessments. Participants allocated to the leaflet and pla-
cebo capsule groups will not be allowed to take the
stress management program and omega-3 PUFA cap-
sules respectively, after 26 weeks. However, they will be
allowed to take these interventions thereafter, and infor-
mation will be collected from these participants.
Assessment measures
Information about depression and anxiety symptoms
(primary outcome), insomnia, burnout, presenteeism,
quality of life, sick leave, consultation about the mental
state of the participant and oxidative stress will be col-
lected at baseline, three months, six months (primary
time point) and 12 months from registration for each
participant (Table 1).
Primary outcome measure
The primary outcome will be the total depression and
anxiety severity changes at week 26 (rated blindly),
assessed using the 14-item HADS [32,33] through their
mobile phone by a blinded rater located at Kyoto Uni-
versity. All the patients will be requested not to reveal
the allocated treatment to the assessors, in order to keep
the assessors’ blindness to the groups.
The total score of the HADS (HADS-T) ranges from 0
to 42, with higher scores indicating more symptoms.
The HADS has two sub-scores, each ranging from 0 to
21: HADS-D (depression) and HADS-A (anxiety). The
defined cutoffs were eight or higher for mild to moder-
ate symptoms and 11 or higher for severe symptoms of
anxiety or depression. The reliability and validity of theJapanese version of the HADS has been confirmed, with
Cronbach’s alpha values of the scale at 0.79 for the
HADS-D and at 0.77 for the HADS-A [22]. The total
score will be used as a measure of the severity of depres-
sion and anxiety symptoms in the present study.
Secondary outcome measures
All other self-reported measures will be collected
through the EDC system, where the participants can
enter their own data at home. Participants will be noti-
fied at 13, 26 and 52 weeks to fill in the assessment
questionnaires within the following 14, 30 and 30 days
through the EDC system, respectively.
Depression and anxiety symptoms
The HADS will be administered at baseline, 13 and 52
weeks as secondary outcomes, as well as at 26 weeks
(the primary outcome).
Major depressive episode
A current major depressive episode, according to (the
Diagnostic and Statistical Manual of Mental Disorders,
4th. Edition (DSM-IV) criteria, will be ascertained using
the Primary Care Evaluation of Mental Disorders
(PRIME-MD) algorithm in the depression module of the
Patient Health Questionnaire (PHQ-9) [23] at baseline,
13, 26 and 52 weeks. The PHQ-9 was developed as a
self-report version of the PRIME-MD that aims at a
DSM-IV diagnosis of several common mental disorders.
The PHQ-9 has been used as an assessment of major de-
pressive disorder, according to DSM-5 [34]. The PHQ-9
consists of the nine diagnostic criteria items, which
make a total score range between 0 and 27. Good test-
retest reliability (intraclass correlation coefficient (ICC)
= 0.92) [35] and internal consistency reliability (Cron-
bach’s alpha = 0.89) [23] have been reported. The
Japanese version has been established through back-
translation [36].
Anxiety
The Generalized Anxiety Disorder 7-item scale (GAD-7)
[37] will be used to assess the severity of anxiety symp-
toms in the participants at baseline, 13, 26 and 52 weeks.
The GAD-7 was developed to screen for and evaluate
the severity of generalized anxiety disorder (GAD) in the
general population. The GAD-7 consists of seven items
and can give a diagnosis according to DSM-IV and
DSM-5. The internal consistency and test-retest reliabil-
ity of the GAD-7 were a Cronbach’s alpha of 0.92 and
intraclass correlation of 0.83, respectively [37]. Total
scores between five and nine, 10 and 14, or 15 and 21
indicate mild, moderate or severe anxiety symptoms, re-
spectively. According to a recently published systematic
review, the GAD-7 was the best performing test for
Table 1 Schedule for the assessments
Entry 7 to 21 days
after entry
13 weeks from entry
(allowing for subsequent 14 days)
26 weeks from entry
(allowing for subsequent 30 days)
52 weeks from entry
(allowing for subsequent 30 days)
Kyoto
University
HADS assessed through telephone x x x x
Allocation guessed by raters x x x
CRC Informed consent, registration to EDC,
information about allocated group
x
Socio-demographic variables (such as age,
academic status, marital status and
partners)
x
Concentrations of omega-3 fatty acids in









PHQ-9 x x x x
GAD-7 x x x x
ISI x x x x
MBI x x x x
BSI x x x x x
HPQ x x x x
EQ-5D x x x x
Numbers of incidents and accidents x x x x
Numbers of visits to clinics x x x x
Numbers of absent days due to any
reason
x x x x
History of taking psychotropic drugs x x x x
Adverse events x x x x
BSI, Bradford Somatic Inventory; CRC, clinical research coordinator; EDC, electronic data capturing; EQ-5D, EuroQol; GAD-7, Generalized Anxiety Disorder 7-item scale; HADS, Hospital Anxiety and Depression Scale; HPQ,
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to 6.0) and a negative likelihood ratio of 0.13 (95% CI:
0.07 to 0.25) [38]. A Japanese version of the GAD-7 has
been developed [39] and the agreement rate of diagnosis
compared to the Mini International Neuropsychiatric
Interview was reported as satisfactory.
Burnout
The Maslach’s Burnout Inventory (MBI) [40] will be
used to assess burnout in nurses. The MBI is a tool for
detecting and measuring the severity of burnout syn-
drome. It is a 22-item questionnaire that assesses the
degree of burnout in terms of three subscales: emotional
exhaustion (EE), depersonalization (DP) and personal ac-
complishment (PA). EE represents feelings of being
emotionally exhausted and having a lack of energy, DP
represents feelings of impersonal responses towards re-
cipients of the service and PA represents feeling of in-
competence. The original English version has a good
validity and reliability, with a Cronbach’s alpha of 0.71 to
0.90 [41,42]. The Japanese version also has good reliabil-
ity, with a Cronbach’s alpha of 0.77, 0.76 and 0.60 for
EE, DP and PA, respectively [43].
Insomnia
The Insomnia Severity Index (ISI) [44,45] will be used to
assess insomnia at baseline, 13, 26 and 52 weeks. The
ISI is now considered a standard global measure for
assessing the severity of insomnia and is used in many
studies [46,47]. Total scores between eight and 14 and
15 and 28 indicate subthreshold insomnia and clinical
insomnia, respectively. The internal consistency of the
ISI has a Cronbach’s alpha of 0.90 in a community popu-
lation [48]. In a clinical population, a difference in score
of −8.4 points (95% CI: −7.1 to −9.4) was associated with
a moderate improvement, as rated by an independent
assessor after treatment [48]. The Japanese version has
been validated [49].
Somatic symptoms
The Bradford Somatic Inventory (BSI) will be used to
measure somatic symptoms at baseline, 13, 26 and 52
weeks. The BSI is a 44-item questionnaire for female sub-
jects about symptoms experienced in the previous month,
which was designed to detect physical symptoms com-
monly related to depressed patients [50]. We selected the
BSI as a measurement for somatic symptoms because
there are no other assessment tools for this purpose in the
Japanese language. The original English version of the BSI
was translated into Japanese by two Japanese psychiatrists
(NW and YM) and back-translated into English by one
psychiatrist (TAF). The translations were then checked by
the original author of the BSI (Professor David B
Mumford). The number of positive items in the BSI willbe used as a measure of the severity of somatic symptoms
in this study. Data from the BSI will be collected through
the EDC on days seven to 21 from entry into the study to
check the test-retest reliability.
Presenteeism
The World Health Organization Heath and Work Per-
formance Questionnaire (HPQ) will be used to assess
presenteeism at baseline, 13, 26 and 52 weeks. The HPQ
is a self-report instrument designed to estimate the work-
place costs of health problems in terms of self-reported
reduced job performance (presenteeism). The HPQ mea-
sures of presenteeism can be used to calculate two scores:
the absolute presenteeism score, obtained by multiplying
the respondent’s response to the second question by 10,
and the relative presenteeism score, obtained by dividing
the first response by the second response, then multiply-
ing by 100. Absolute and relative presenteeism scores will
be used in this study.
The validity of the scale has been confirmed in previ-
ous studies [51,52]. The Japanese version of the HPQ
was used in the World Mental Health Survey in Japan
[53]. The area under the curve values for absolute and
relative presenteeism in relation to future absences due
to mental disease were 0.71 (95% CI: 0.62 to 0.80) and
0.65 (95% CI: 0.55 to 0.75), respectively [54].
Quality of life
The EuroQol (EQ-5D) [55] will be used to assess health-
related quality of life (QoL) at baseline, 13, 26 and 52
weeks. The EQ-5D is a standardized instrument used as
a measure of health outcome and is applicable to a wide
range of health conditions and treatments. The five do-
mains include mobility, self-care, usual activities, pain
and/or discomfort, and anxiety and/or depression. There
are three levels of severity: no problems, some or moder-
ate problems and severe or extreme problems. Each pat-
tern of responses is allocated to an individual utility
score, which ranges from 0 (death) to one (perfect
health). The Japanese version has been developed [56].
The test-retest reliability of the Japanese version was
0.996, and Cronbach’s alpha was 0.827 [57].
Oxidative stress
Oxidative stress and antioxidant levels will be evaluated at
the baseline and three-month assessments among the
nurses working for the National Center of Neurology and
Psychiatry Hospital and National Disaster Medical Center.
Oxidative stress is the imbalance between oxidative stress
and antioxidant defenses. High oxidative stress or low anti-
oxidant status are becoming increasingly recognized as bio-
logical mechanisms associated with poor health outcomes
and the progression of a wide range of diseases [58,59]. An
association between depression and oxidative stress has
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however, the conclusions seem inconsistent due to large
heterogeneity among the included studies, with an I2 of
80% and possible selection bias as the studies did not cover
a broad range of depression. Moreover, the meta-analysis
included only cross-sectional studies; therefore, associations
between changes in depression and oxidative stress remain
unclear.
In the present study, we will use reactive oxygen
metabolite-derived compounds (d-ROMs) and biological
antioxidant potential (BAP) tests [61] to evaluate oxidative
stress and antioxidant levels, respectively, as used in previ-
ous studies [62,63].
Adverse events
An adverse event is defined as any unwanted or unin-
tended signs (including laboratory exams, suicidal and
self-harm behaviors and very unstable mental states),
symptoms or disease seen in trial participants, regardless
of the causal relationship with the study intervention.
Information about any possible adverse events will be
collected during the intervention period through the
EDC. Participants will be encouraged to input these data
via emails at fixed intervals. Information about the sever-
ity and degree of adverse events affecting normal life will
also be collected. When the severity of severe for adverse
events or the degree affecting usual life of moderate or
severe due to adverse eventsis presented, the participant
will be contacted through telephone or email by a CRC,
and termination of the intervention will be discussed.
Adverse events will be classified into major adverse
events if they may lead to death or to enduring severe
impairment, depending on participants’ conditions and
circumstances. Major adverse events shall be reported to
the relevant section of the Ministry of Health, Labor and
Welfare, as well as to the heads of all research centers
and recruiting hospitals.
Other outcomes
Information about sick leave, consultations on personal
mental state and about discontinuation of the allocated
interventions will be collected through the EDC.
Sample size
The sample size was based on a power analysis conducted
for the HADS scores. There are no previous reports asso-
ciated with the stress management program, in terms of
nurse-to-nurse interventions, that can contribute to the
power calculation of our trial. Based on trials that have
used nurses as therapists and the HADS as the primary
outcome, one trial has examined the efficacy of cognitive
behavioral therapy conducted by nurses for depression in
the elderly after lumber fracture operations, and a differ-
ence of 3.7 was found compared with treatment as usual[64]. To the best of our knowledge, there have been no
reports assessing treatment with omega-3 fatty acids for
depression or anxiety in nurses. One systematic review
and meta-analysis has shown that treatment with omega-
3, ≥60% EPA and ≤40% DHA led to an effect size
of −0.026 (95% CI: −0.200 to 0.148), when compared with
a placebo [65]. Therefore, the mean difference in the
HADS scores was estimated to be 4 ± 6 (SD) between the
stress management program and leaflet groups, and be-
tween the omega-3 fatty acids and placebo groups. To de-
tect a significant difference at P = 0.05 (two-tailed) with a
power of 0.9, it was calculated that 48 patients would be
required for each of the arms in both comparisons. Thus,
allowing for a 20% dropout rate, 60 participants would
need to be recruited per group. In the present factorial-
design RCT, 30 participants would be necessary for each
of the four groups.Data management and analysis
All of the participants who are randomized at baseline will
be included in the primary analyses (intention-to-treat
(ITT)). First, a descriptive analysis of the variables at base-
line will be performed. We do not plan any statistical tests
to detect a difference at baseline among the trial arms be-
cause we aim to avoid multiple tests, and the decision to
adjust for baseline data in RCTs should not be determined
by whether baseline differences are statistically significant
[66]. However, when clinically important differences at
baseline are noted from a clinician’s point of view, a sensi-
tivity analysis will be performed by adjusting for all such
possible confounds.
Second, for the primary outcome and all the continu-
ous outcomes assessed at 26 and 52 weeks, differences
among groups will be examined using a mixed-model
repeated measures analysis. When missing data exist for
categorical variables, which are all negative outcomes,
an ITT principal will be applied by assuming that all
dropouts did not satisfy the outcomes. However, per
protocol analyses, where only data from completers are
incorporated, will also be presented according to a re-
cent recommendation [67]. We also plan to calculate a
number needed to treat (NNT) with a 95% CI if a statis-
tically significant difference among the groups is ob-
served in dichotomous data.
A P value of <0.05 will be set to test the null hypothesis
for all analyses. Although we understand that this decision
might lead to errors in multiple tests, the present trial is
the first of its kind to examine prevention interventions in
this type of workplace; therefore, we have considered that
avoiding beta errors is preferable over alpha errors. How-
ever, 95% CIs will always be presented for differences
among groups. We will not perform interim analyses to
examine the study hypotheses.
Watanabe et al. Trials  (2015) 16:36 Page 9 of 12Sensitivity analysis
Per protocol analyses, where only data from completers
are incorporated to an analysis of covariance that adjusts
for baseline data, will be performed as sensitivity ana-
lyses for all the continuous outcomes.
Data monitoring
The trial will be supervised by the Data Monitoring and
Safety Management Committee. The committee consists
of three independent experts in research on psychother-
apy and nutrient interventions and research method-
ology. Data regarding all outcomes will be sent to the
committee twice a year and inspected. The members of
the committee are independent from the sponsor and
competing interests of the present study.
Publication policy
The protocol and the results of all outcomes will be
published in a peer-reviewed medical journal. The re-
sults shall be reflected in treatment guidelines and sys-
tematic reviews.
Study period
The study period of this trial will be between June 2014
and March 2016, with the participant entry period being
between June 2014 and March 2015.
Ethical issues
The present study complies with the ethical guidelines for
clinical studies published by the Japanese Ministry of
Health Labor and Welfare, as well as the ethical principles
established for research on humans stipulated in the Dec-
laration of Helsinki and further amendments thereto.
The study protocol has been approved by the institu-
tional review boards of the National Center of Neurology
and Psychiatry on 16 May 16 2014 (approval number:
A2014-017) and of Toyama University on 16 June 2014
(approval number: 26–24). If important protocol modifi-
cations such as changes to eligibility criteria, outcomes or
analyses are needed for any reason, the investigators will
communicate this with the review boards.
Written informed consent will be obtained from all
participants included in this study. Participants will be
informed that they can withdraw from the study at any
time without stating the reason, and that their with-
drawal will never lead to refusal of any other services.
Data for each participant will be handled with sequen-
tially allocated numbers to keep participant’s confidenti-
ality. Participants’ personal information will also be
anonymized with sequentially allocated numbers.
Discussion
To the best of our knowledge, this study represents the
first study to investigate the effectiveness of preventiveinterventions on depression and anxiety symptoms among
hospital nurses. In addition to these symptoms, approxi-
mately one in four nurses who are shift workers in Japan
suffer from shift work disorder [68], which is characterized
by excessive sleepiness and/or insomnia associated with
their shift work schedule [69]. The high prevalence of
these common psychiatric symptoms is probably due to
the high responsibility, need for high levels of expertise
and relatively low reward associated with the nursing pro-
fession. A significant association was found between de-
pressive symptoms and effort-reward imbalance, with an
odds ratio (OR) of 10.8, and between esteem-reward im-
balance, with an OR of 3.2 in nurse managers working in
hospitals in France [70].
It would be hard to restructure the proportion of hos-
pital workers and increase the number of nurses, or to re-
duce the responsibility and increase the salary of nurses.
However, realistic interventions are needed to empower
resilience in order to alleviate psychological distress
among nurses. Lifestyle interventions, such as diet and
psychotherapeutic approaches, are highly desirable op-
tions. When an effective preventive intervention has been
established, the results may not only lead to the mainten-
ance of a healthy mental state in nurses, but also a better
quality of care for inpatients. We believe that the present
study will be able to contribute to this goal.
The present study is not without methodological limi-
tations. First, a previous observational study with a large
sample size has reported that an increase in a nurses’
workload by one patient, and no bachelor’s degree-level
education led to an increase in preventable hospital
deaths [71]. We do not plan to collect information about
patient outcomes, because inpatients from the hospitals
included in the study are usually discharged within ap-
proximately 14 days, and many nurses are involved in
the care of each patient. Therefore, we have decided a
priori not to investigate the efficacy of interventions on
patient outcomes.
Second, some essential organizational characteristics,
including decision-making latitude and quality and
quantity of support from peer nurses, are not considered
in the study. All of the hospitals that are enrolled in the
study are funded by national or local government and
located in the capital city of Japan. Neither private nor
rural hospitals are included. These may have an effect
on the mental health of nurses and therefore these im-
pose a negative impact on the applicability of findings
from the study. However, the methodology of quantita-
tively measuring decision-making latitude, and quality
and quantity of support from peer nurses in various dis-
ciplines has not been confirmed [6]. The hospitals in this
study are core general hospitals in the district and we
believe that they are representative among hospitals in
developed countries.
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in other countries, one may doubt the applicability of the
findings about omega-3 PUFAs from the present study. A
high consumption of fish has been reported to be corre-
lated with a lower countrywide prevalence of major de-
pression, according to a study published in 1998 [72].
However, the Japanese diet has been changing to a more
Western diet similar to countries in other parts of the
world. Moreover, we have excluded participants who con-
sume fish as the main course of a meal four or more times
per week. Therefore, we believe that our findings can be
applied to the other countries.
In conclusion, this paper outlines the background and
methods of a randomized trial evaluating the promising
interventions for maintaining a healthy mental state in
hospital nurses.
Trial status
The randomized trial is currently in the phase of partici-
pant enrolment and follow-up.
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